![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CBL |
Gene summary for CBL |
![]() |
Gene information | Species | Human | Gene symbol | CBL | Gene ID | 867 |
Gene name | Cbl proto-oncogene | |
Gene Alias | C-CBL | |
Cytomap | 11q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P22681 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
867 | CBL | LZE4T | Human | Esophagus | ESCC | 1.29e-06 | 1.76e-01 | 0.0811 |
867 | CBL | LZE20T | Human | Esophagus | ESCC | 4.46e-02 | 5.96e-02 | 0.0662 |
867 | CBL | LZE22D1 | Human | Esophagus | HGIN | 4.11e-03 | 2.19e-01 | 0.0595 |
867 | CBL | LZE22T | Human | Esophagus | ESCC | 1.71e-12 | 7.21e-01 | 0.068 |
867 | CBL | LZE24T | Human | Esophagus | ESCC | 6.27e-15 | 2.81e-01 | 0.0596 |
867 | CBL | P2T-E | Human | Esophagus | ESCC | 1.06e-05 | 9.22e-02 | 0.1177 |
867 | CBL | P4T-E | Human | Esophagus | ESCC | 4.16e-16 | 3.61e-01 | 0.1323 |
867 | CBL | P5T-E | Human | Esophagus | ESCC | 5.82e-08 | 1.64e-01 | 0.1327 |
867 | CBL | P8T-E | Human | Esophagus | ESCC | 3.13e-07 | 1.16e-01 | 0.0889 |
867 | CBL | P9T-E | Human | Esophagus | ESCC | 9.93e-13 | 1.12e-01 | 0.1131 |
867 | CBL | P10T-E | Human | Esophagus | ESCC | 2.10e-07 | 1.34e-01 | 0.116 |
867 | CBL | P11T-E | Human | Esophagus | ESCC | 4.70e-10 | 2.85e-01 | 0.1426 |
867 | CBL | P12T-E | Human | Esophagus | ESCC | 5.27e-08 | 2.15e-01 | 0.1122 |
867 | CBL | P15T-E | Human | Esophagus | ESCC | 3.88e-05 | 6.25e-02 | 0.1149 |
867 | CBL | P16T-E | Human | Esophagus | ESCC | 1.64e-04 | 1.40e-01 | 0.1153 |
867 | CBL | P17T-E | Human | Esophagus | ESCC | 3.31e-05 | 1.70e-01 | 0.1278 |
867 | CBL | P19T-E | Human | Esophagus | ESCC | 5.34e-03 | 1.80e-01 | 0.1662 |
867 | CBL | P20T-E | Human | Esophagus | ESCC | 2.61e-03 | 5.17e-02 | 0.1124 |
867 | CBL | P21T-E | Human | Esophagus | ESCC | 5.98e-20 | 4.15e-01 | 0.1617 |
867 | CBL | P22T-E | Human | Esophagus | ESCC | 2.50e-06 | 7.85e-02 | 0.1236 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0510039 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05100114 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBL | SNV | Missense_Mutation | novel | c.2184C>A | p.Ser728Arg | p.S728R | P22681 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CBL | SNV | Missense_Mutation | novel | c.2324N>T | p.Asp775Val | p.D775V | P22681 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CBL | insertion | Frame_Shift_Ins | novel | c.2224_2225insCATCTAT | p.Thr745IlefsTer10 | p.T745Ifs*10 | P22681 | protein_coding | TCGA-ZS-A9CG-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
CBL | SNV | Missense_Mutation | c.1237N>C | p.Gly413Arg | p.G413R | P22681 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
CBL | SNV | Missense_Mutation | c.2393C>A | p.Ser798Tyr | p.S798Y | P22681 | protein_coding | deleterious_low_confidence(0.01) | benign(0.084) | TCGA-55-8620-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
CBL | SNV | Missense_Mutation | c.203N>T | p.Arg68Leu | p.R68L | P22681 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-69-7980-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CBL | SNV | Missense_Mutation | c.1202N>T | p.Cys401Phe | p.C401F | P22681 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CBL | SNV | Missense_Mutation | c.460C>G | p.Leu154Val | p.L154V | P22681 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-MP-A4SY-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
CBL | SNV | Missense_Mutation | c.1450C>T | p.Pro484Ser | p.P484S | P22681 | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CBL | SNV | Missense_Mutation | novel | c.539N>T | p.Arg180Leu | p.R180L | P22681 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-18-3421-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | Fasudil | FASUDIL | 26177294 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | ANTISENSE OLIGONUCLEOTIDES | 8849724 | ||
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | Gemcitabine | GEMCITABINE | 25348515 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | DASATINIB | DASATINIB | 23696637 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | SU11274 | 28835699 | ||
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | N/A | 26230957,23690417,19901108 | ||
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | Quizartinib | QUIZARTINIB | 22990016 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | IL-2 | ALDESLEUKIN | 9461587 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | Erlotinib | ERLOTINIB | 25348515 | |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | FLT3-LIGAND | 17446348 |
Page: 1 2 |